Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 3
1994 1
1995 1
1997 5
1998 10
1999 1
2000 2
2002 3
2003 2
2004 5
2005 1
2006 1
2007 2
2008 1
2010 2
2011 2
2012 4
2013 6
2014 5
2015 2
2016 3
2017 2
2018 6
2019 4
2020 3
2021 2
2022 3
2023 1
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
A novel antibiotic class targeting the lipopolysaccharide transporter.
Zampaloni C, Mattei P, Bleicher K, Winther L, Thäte C, Bucher C, Adam JM, Alanine A, Amrein KE, Baidin V, Bieniossek C, Bissantz C, Boess F, Cantrill C, Clairfeuille T, Dey F, Di Giorgio P, du Castel P, Dylus D, Dzygiel P, Felici A, García-Alcalde F, Haldimann A, Leipner M, Leyn S, Louvel S, Misson P, Osterman A, Pahil K, Rigo S, Schäublin A, Scharf S, Schmitz P, Stoll T, Trauner A, Zoffmann S, Kahne D, Young JAT, Lobritz MA, Bradley KA. Zampaloni C, et al. Among authors: boess f. Nature. 2024 Jan;625(7995):566-571. doi: 10.1038/s41586-023-06873-0. Epub 2024 Jan 3. Nature. 2024. PMID: 38172634 Free PMC article.
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: boess fg. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Molecular biology of 5-HT receptors.
Boess FG, Martin IL. Boess FG, et al. Neuropharmacology. 1994 Mar-Apr;33(3-4):275-317. doi: 10.1016/0028-3908(94)90059-0. Neuropharmacology. 1994. PMID: 7984267 Review. No abstract available.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: boess fg. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
The putative 5-ht6 receptor: localization and function.
Sleight AJ, Boess FG, Bös M, Bourson A. Sleight AJ, et al. Among authors: boess fg. Ann N Y Acad Sci. 1998 Dec 15;861:91-6. doi: 10.1111/j.1749-6632.1998.tb10178.x. Ann N Y Acad Sci. 1998. PMID: 9928244 Review.
Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects.
Wong DF, Comley RA, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S, Vozzi C, Boess F, Oh E, Lyketsos CG, Honer M, Gobbi L, Klein G, George N, Gapasin L, Kitzmiller K, Roberts J, Sevigny J, Nandi A, Brasic J, Mishra C, Thambisetty M, Mogekar A, Mathur A, Albert M, Dannals RF, Borroni E. Wong DF, et al. Among authors: boess f. J Nucl Med. 2018 Dec;59(12):1869-1876. doi: 10.2967/jnumed.118.209916. Epub 2018 May 4. J Nucl Med. 2018. PMID: 29728519 Free PMC article.
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort.
Simuni T, Merchant K, Brumm MC, Cho H, Caspell-Garcia C, Coffey CS, Chahine LM, Alcalay RN, Nudelman K, Foroud T, Mollenhauer B, Siderowf A, Tanner C, Iwaki H, Sherer T, Marek K; Parkinson’s Progression Marker Initiative Authors. Simuni T, et al. NPJ Parkinsons Dis. 2022 Oct 22;8(1):140. doi: 10.1038/s41531-022-00404-w. NPJ Parkinsons Dis. 2022. PMID: 36273008 Free PMC article.
Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients.
Alcalay RN, Wolf P, Chiang MSR, Helesicova K, Zhang XK, Merchant K, Hutten SJ, Scherzer C, Caspell-Garcia C, Blauwendraat C, Foroud T, Nudelman K, Gan-Or Z, Simuni T, Chahine LM, Levy O, Zheng D, Li G, Sardi SP; Parkinson’s Progression Markers Initiative. Alcalay RN, et al. Ann Clin Transl Neurol. 2020 Oct;7(10):1816-1830. doi: 10.1002/acn3.51164. Epub 2020 Sep 5. Ann Clin Transl Neurol. 2020. PMID: 32888397 Free PMC article.
Assessment of hepatotoxic liabilities by transcript profiling.
Ruepp S, Boess F, Suter L, de Vera MC, Steiner G, Steele T, Weiser T, Albertini S. Ruepp S, et al. Among authors: boess f. Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):161-70. doi: 10.1016/j.taap.2005.05.008. Toxicol Appl Pharmacol. 2005. PMID: 15990132 Review.
80 results